CA2835453A1 - Genetically engineered growth factor variants - Google Patents
Genetically engineered growth factor variants Download PDFInfo
- Publication number
- CA2835453A1 CA2835453A1 CA2835453A CA2835453A CA2835453A1 CA 2835453 A1 CA2835453 A1 CA 2835453A1 CA 2835453 A CA2835453 A CA 2835453A CA 2835453 A CA2835453 A CA 2835453A CA 2835453 A1 CA2835453 A1 CA 2835453A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- cell
- noc
- dimer
- delta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003102 growth factor Substances 0.000 title claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 300
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 266
- 239000000539 dimer Substances 0.000 claims description 307
- 235000018102 proteins Nutrition 0.000 claims description 237
- 210000004027 cell Anatomy 0.000 claims description 220
- 210000000130 stem cell Anatomy 0.000 claims description 134
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 110
- 102100034256 Mucin-1 Human genes 0.000 claims description 110
- 230000015572 biosynthetic process Effects 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 82
- 239000000178 monomer Substances 0.000 claims description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 43
- 238000006471 dimerization reaction Methods 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 230000027455 binding Effects 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 33
- 230000001413 cellular effect Effects 0.000 claims description 24
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims description 17
- 108091023040 Transcription factor Proteins 0.000 claims description 17
- 102000040945 Transcription factor Human genes 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 17
- 235000018417 cysteine Nutrition 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 14
- 150000001945 cysteines Chemical class 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 7
- 210000001082 somatic cell Anatomy 0.000 claims description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 6
- 230000002463 transducing effect Effects 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000009395 genetic defect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000004681 ovum Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 108090000144 Human Proteins Proteins 0.000 claims description 2
- 102000003839 Human Proteins Human genes 0.000 claims description 2
- 108090000143 Mouse Proteins Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 102220484604 Nucleoside diphosphate kinase A_P96S_mutation Human genes 0.000 claims 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 63
- 230000012010 growth Effects 0.000 description 57
- 102000005962 receptors Human genes 0.000 description 48
- 108020003175 receptors Proteins 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 45
- 239000003446 ligand Substances 0.000 description 45
- 239000000499 gel Substances 0.000 description 37
- 238000003752 polymerase chain reaction Methods 0.000 description 37
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 34
- 230000010261 cell growth Effects 0.000 description 33
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 33
- 210000001778 pluripotent stem cell Anatomy 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 27
- 210000004940 nucleus Anatomy 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 25
- 230000006870 function Effects 0.000 description 25
- 108010009202 Growth Factor Receptors Proteins 0.000 description 22
- 102000009465 Growth Factor Receptors Human genes 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 238000000338 in vitro Methods 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 21
- 239000002105 nanoparticle Substances 0.000 description 21
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 20
- 238000012512 characterization method Methods 0.000 description 20
- 230000002441 reversible effect Effects 0.000 description 20
- 230000035772 mutation Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 238000000746 purification Methods 0.000 description 16
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 239000013545 self-assembled monolayer Substances 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 10
- 239000010931 gold Substances 0.000 description 10
- 229910052737 gold Inorganic materials 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000447 dimerizing effect Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000012146 running buffer Substances 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 230000008719 thickening Effects 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108091028684 Mir-145 Proteins 0.000 description 4
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000030648 nucleus localization Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 108010084592 Saporins Proteins 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 102000052119 human NME1 Human genes 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 101100454433 Biomphalaria glabrata BG01 gene Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000006151 minimal media Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101150098207 NAAA gene Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010087558 pectate lyase Proteins 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002094 self assembled monolayer Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161484052P | 2011-05-09 | 2011-05-09 | |
| US61/484,052 | 2011-05-09 | ||
| PCT/US2012/036975 WO2012154759A2 (en) | 2011-05-09 | 2012-05-08 | Genetically engineered growth factor variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2835453A1 true CA2835453A1 (en) | 2012-11-15 |
Family
ID=47139949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2835453A Pending CA2835453A1 (en) | 2011-05-09 | 2012-05-08 | Genetically engineered growth factor variants |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20140065113A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2707021B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2014517690A (cg-RX-API-DMAC7.html) |
| CN (2) | CN103930439A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012253652B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2835453A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL229316B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012154759A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2686418A4 (en) | 2011-03-17 | 2015-04-22 | Minerva Biotechnologies Corp | METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS |
| AU2012253652B2 (en) * | 2011-05-09 | 2017-07-06 | Minerva Biotechnologies Corporation | Genetically engineered growth factor variants |
| IL240695B2 (en) * | 2013-02-20 | 2024-03-01 | Minerva Biotechnologies Corp | Nme inhibitors and methods of using nme inhibitors |
| CA2963425A1 (en) * | 2014-10-16 | 2016-04-21 | Counsyl, Inc. | Variant caller |
| IL299332A (en) | 2020-06-26 | 2023-02-01 | Minerva Biotechnologies Corp | Anti-nme antibody and method of treating cancer or cancer metastasis |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| CN117736272B (zh) * | 2024-02-19 | 2024-04-30 | 四川省医学科学院·四川省人民医院 | 一种具有促成骨功能的生物活性多肽 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE206129T1 (de) * | 1989-10-18 | 2001-10-15 | Us Health | Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper |
| US5958671A (en) * | 1996-04-23 | 1999-09-28 | Presidents And Fellows Of Harvard College | Methods and compositions for regulating T cell subsets by modulating transcription factor activity |
| US20050112607A1 (en) * | 1999-01-23 | 2005-05-26 | Bamdad Cynthia C. | Rapid and sensitive detection of protein aggregation |
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| ATE407697T1 (de) * | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| EP1200479B1 (en) * | 1999-08-09 | 2006-02-01 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US20020169290A1 (en) * | 2000-11-02 | 2002-11-14 | Claus Bornaes | New multimeric interferon beta polypeptides |
| AU2002212108A1 (en) * | 2000-11-02 | 2002-05-15 | Maxygen Aps | Single-chain multimeric polypeptides |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| JP2005503120A (ja) * | 2001-03-27 | 2005-02-03 | マサチューセッツ インスティテュート オブ テクノロジー | Ｆｇｆダイマー化に関する方法及び生成物 |
| EP1353182A3 (en) * | 2002-04-12 | 2004-02-04 | Smithkline Beecham Corporation | Method of predicting cell-based assay results using binding profiles |
| AU2003268345A1 (en) * | 2002-09-24 | 2004-04-19 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| AU2004252170B2 (en) * | 2003-06-27 | 2011-01-27 | Biogen Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US20050054752A1 (en) * | 2003-09-08 | 2005-03-10 | O'brien John P. | Peptide-based diblock and triblock dispersants and diblock polymers |
| BRPI0507174A (pt) * | 2004-01-28 | 2008-04-01 | Syntonix Pharmaceuticals Inc | proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CN101652469B (zh) * | 2006-12-06 | 2014-04-16 | 米纳瓦生物技术公司 | 用于鉴定和操作细胞的方法 |
| CA2729810A1 (en) * | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | Tgf-.beta. antagonist multi-target binding proteins |
| US11898160B2 (en) * | 2008-10-09 | 2024-02-13 | Minerva Biotechnologies Corporation | Method for maintaining pluripotency in cells |
| MX2011013385A (es) * | 2009-06-11 | 2012-05-29 | Minerva Biotechnologies Corp | Metodos para cultivar celulas madre y celulas progenitoras. |
| US20130040845A1 (en) * | 2010-02-16 | 2013-02-14 | Immune Disease Institute, Inc. | Method for screening receptors/ligands interactions |
| EP2686418A4 (en) * | 2011-03-17 | 2015-04-22 | Minerva Biotechnologies Corp | METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS |
| AU2012253652B2 (en) * | 2011-05-09 | 2017-07-06 | Minerva Biotechnologies Corporation | Genetically engineered growth factor variants |
-
2012
- 2012-05-08 AU AU2012253652A patent/AU2012253652B2/en active Active
- 2012-05-08 CN CN201280034119.XA patent/CN103930439A/zh active Pending
- 2012-05-08 JP JP2014510413A patent/JP2014517690A/ja active Pending
- 2012-05-08 CN CN202010915430.1A patent/CN112028985A/zh active Pending
- 2012-05-08 EP EP12782984.4A patent/EP2707021B1/en active Active
- 2012-05-08 WO PCT/US2012/036975 patent/WO2012154759A2/en not_active Ceased
- 2012-05-08 CA CA2835453A patent/CA2835453A1/en active Pending
-
2013
- 2013-11-07 IL IL229316A patent/IL229316B/en active IP Right Grant
- 2013-11-11 US US14/077,061 patent/US20140065113A1/en not_active Abandoned
-
2016
- 2016-10-18 JP JP2016204089A patent/JP6717725B2/ja active Active
-
2019
- 2019-06-20 US US16/447,812 patent/US20200062812A1/en not_active Abandoned
- 2019-11-25 JP JP2019211946A patent/JP2020039359A/ja active Pending
-
2021
- 2021-11-29 JP JP2021193554A patent/JP2022031824A/ja active Pending
-
2024
- 2024-01-19 JP JP2024006988A patent/JP2024056702A/ja active Pending
- 2024-04-19 US US18/640,690 patent/US20240294590A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012154759A3 (en) | 2014-05-01 |
| EP2707021A4 (en) | 2015-08-05 |
| EP2707021B1 (en) | 2024-02-21 |
| IL229316B (en) | 2020-02-27 |
| EP2707021C0 (en) | 2024-02-21 |
| US20140065113A1 (en) | 2014-03-06 |
| IL229316A0 (en) | 2014-01-30 |
| JP2024056702A (ja) | 2024-04-23 |
| EP2707021A2 (en) | 2014-03-19 |
| CN112028985A (zh) | 2020-12-04 |
| JP2020039359A (ja) | 2020-03-19 |
| JP6717725B2 (ja) | 2020-07-01 |
| JP2017061471A (ja) | 2017-03-30 |
| WO2012154759A2 (en) | 2012-11-15 |
| AU2012253652B2 (en) | 2017-07-06 |
| US20200062812A1 (en) | 2020-02-27 |
| US20240294590A1 (en) | 2024-09-05 |
| AU2012253652A1 (en) | 2013-11-28 |
| JP2022031824A (ja) | 2022-02-22 |
| JP2014517690A (ja) | 2014-07-24 |
| CN103930439A (zh) | 2014-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240294590A1 (en) | Nucleic acid encoding genetically engineered growth factor variants | |
| JP7700159B2 (ja) | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 | |
| Walker et al. | Structural basis for potency differences between GDF8 and GDF11 | |
| JP7142915B2 (ja) | ラクトフェリン／アルブミン融合タンパク質及びその製造方法 | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| JP5787757B2 (ja) | Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質 | |
| JP2022046544A (ja) | ｓｙｎＴａｃポリペプチド及びその使用 | |
| US8926972B2 (en) | Anti-angiogenesis fusion proteins | |
| JP6809789B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP2023082052A (ja) | キメラ抗原受容体およびその使用 | |
| TWI237056B (en) | Fusion protein having enhanced in vivo activity of erythropoietin | |
| JP2020506701A (ja) | 組織特異的Ｗｎｔシグナル増強分子およびその使用 | |
| AU2015205918A1 (en) | Methods for increasing thermogenic adipocytes | |
| JP2017530099A (ja) | Ｗｎｔシグナリングアゴニスト分子 | |
| JPH09512176A (ja) | 二価のタンパク質、調製及び利用 | |
| CN105377893A (zh) | 三聚体抗原结合分子 | |
| JP2018538356A (ja) | 組織修復のための二重特異性治療用タンパク質 | |
| CN106255699A (zh) | 细胞穿透肽和使用其输送生物活性物质的方法 | |
| JP2021526835A (ja) | 二機能性および三機能性融合タンパク質およびその使用 | |
| CN101914161B (zh) | 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途 | |
| JP2020529847A (ja) | がんの処置のための方法および組成物 | |
| KR20240135690A (ko) | 절두된 및 융합 단백질 | |
| US11026996B2 (en) | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling | |
| CN111479820A (zh) | 重组多肽中的工程化o-糖基化及其用途 | |
| WO2020241827A1 (ja) | Ａｌｋを標的とするキメラ抗原受容体発現細胞 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170426 |
|
| EEER | Examination request |
Effective date: 20170426 |
|
| EEER | Examination request |
Effective date: 20170426 |
|
| EEER | Examination request |
Effective date: 20170426 |
|
| EEER | Examination request |
Effective date: 20170426 |
|
| EEER | Examination request |
Effective date: 20170426 |
|
| EEER | Examination request |
Effective date: 20170426 |